MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MBRX had -$854K decrease in cash & cash equivalents over the period. -$7,223K in free cash flow.

Cash Flow Overview

Change in Cash
-$854K
Free Cash flow
-$7,223K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-35,036 -14,076
Depreciation and amortization
22 59
Stock-based compensation
303 902
Change in fair value of warrant liability
17,632 -18,663
Loss on issuance of warrant liabilities
-12,812 -18,150
Operating lease, net
-3 116
Transaction costs allocated to warrant liabilities
-1,258 2,995
Prepaid expenses and other assets
-337 1,503
Accounts payable
-1,483 1,526
Accrued expenses and other current liabilities
-549 348
Net cash used in operating activities
-7,223 -10,146
Purchase of fixed assets
0 0
Net cash used in investing activities
0 0
Proceeds from exercise of warrants
1,111 10
Payment of tax liability for vested restricted stock units
0 0
Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs
5,264 13,412
Net cash provided by financing activities
6,375 13,422
Effect of exchange rate changes on cash and cash equivalents
-6 3
Net increase (decrease) in cash and cash equivalents
-854 3,279
Cash and cash equivalents at beginning of period
4,278 -
Cash and cash equivalents at end of period
6,703 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. (MBRX)